Your browser doesn't support javascript.
loading
Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis.
Gustot, Thierry; Fernandez, Javier; Garcia, Elisabet; Morando, Filippo; Caraceni, Paolo; Alessandria, Carlo; Laleman, Wim; Trebicka, Jonel; Elkrief, Laure; Hopf, Corinna; Solís-Munoz, Pablo; Saliba, Faouzi; Zeuzem, Stefan; Albillos, Augustin; Benten, Daniel; Montero-Alvarez, José Luis; Chivas, Maria Teresa; Concepción, Mar; Córdoba, Juan; McCormick, Aiden; Stauber, Rudolf; Vogel, Wolfgang; de Gottardi, Andrea; Welzel, Tania M; Domenicali, Marco; Risso, Alessandro; Wendon, Julia; Deulofeu, Carme; Angeli, Paolo; Durand, François; Pavesi, Marco; Gerbes, Alexander; Jalan, Rajiv; Moreau, Richard; Ginés, Pere; Bernardi, Mauro; Arroyo, Vicente.
Afiliación
  • Gustot T; Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Fernandez J; Hospital Clínic, Barcelona, Spain.
  • Garcia E; Data Management Center of the EASL-CLIF Consortium, CIBEReHD, Barcelona, Spain.
  • Morando F; University of Padova, Padova, Italy.
  • Caraceni P; Policlinico St Orsola Malpighi, Bologna, Italy.
  • Alessandria C; University of Turin, Turin, Italy.
  • Laleman W; University Hospital Gasthuisberg, Leuven, Belgium.
  • Trebicka J; University Hospital Bonn, Bonn, Germany.
  • Elkrief L; Hôpital Beaujon, Clichy, France.
  • Hopf C; University of Munich, Klinikum der LMU, Munich, Germany.
  • Solís-Munoz P; Kinǵs College Hospital, London, London, UK.
  • Saliba F; Hopital Paul Brousse, Villejuif, France.
  • Zeuzem S; J.W. Goethe University Hospital, Frankfurt, Germany.
  • Albillos A; Hospital Ramón y Cajal, Madrid, Spain.
  • Benten D; University Hospital Hambourg-Eppendorf, Germany.
  • Montero-Alvarez JL; Reina Sofía University Hospital, Córdoba, Spain.
  • Chivas MT; Hospital Gregorio Marañón, Madrid, Spain.
  • Concepción M; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Córdoba J; Hospital Vall d'Hebron, Barcelona, Spain.
  • McCormick A; St Vincent's University Hospital, Dublin, Ireland.
  • Stauber R; Medical University of Graz, Graz, Austria.
  • Vogel W; Medical University of Innsbruck, Innsbruck, Austria.
  • de Gottardi A; University of Berne, Berne, Switzerland.
  • Welzel TM; J.W. Goethe University Hospital, Frankfurt, Germany.
  • Domenicali M; Policlinico St Orsola Malpighi, Bologna, Italy.
  • Risso A; University of Turin, Turin, Italy.
  • Wendon J; Kinǵs College Hospital, London, London, UK.
  • Deulofeu C; Data Management Center of the EASL-CLIF Consortium, CIBEReHD, Barcelona, Spain.
  • Angeli P; University of Padova, Padova, Italy.
  • Durand F; Hôpital Beaujon, Clichy, France.
  • Pavesi M; Data Management Center of the EASL-CLIF Consortium, CIBEReHD, Barcelona, Spain.
  • Gerbes A; University of Munich, Klinikum der LMU, Munich, Germany.
  • Jalan R; Royal Free Hospital, London, UK.
  • Moreau R; Hôpital Beaujon, Clichy, France.
  • Ginés P; Hospital Clínic, Barcelona, Spain.
  • Bernardi M; EASL-CLIF Consortium, Barcelona, Spain.
  • Arroyo V; EASL-CLIF Consortium, Barcelona, Spain.
Hepatology ; 62(1): 243-52, 2015 Jul.
Article en En | MEDLINE | ID: mdl-25877702
UNLABELLED: Acute-on-chronic liver failure (ACLF) is characterized by acute decompensation (AD) of cirrhosis, organ failure(s), and high 28-day mortality. We investigated whether assessments of patients at specific time points predicted their need for liver transplantation (LT) or the potential futility of their care. We assessed clinical courses of 388 patients who had ACLF at enrollment, from February through September 2011, or during early (28-day) follow-up of the prospective multicenter European Chronic Liver Failure (CLIF) ACLF in Cirrhosis study. We assessed ACLF grades at different time points to define disease resolution, improvement, worsening, or steady or fluctuating course. ACLF resolved or improved in 49.2%, had a steady or fluctuating course in 30.4%, and worsened in 20.4%. The 28-day transplant-free mortality was low-to-moderate (6%-18%) in patients with nonsevere early course (final no ACLF or ACLF-1) and high-to-very high (42%-92%) in those with severe early course (final ACLF-2 or -3) independently of initial grades. Independent predictors of course severity were CLIF Consortium ACLF score (CLIF-C ACLFs) and presence of liver failure (total bilirubin ≥12 mg/dL) at ACLF diagnosis. Eighty-one percent had their final ACLF grade at 1 week, resulting in accurate prediction of short- (28-day) and mid-term (90-day) mortality by ACLF grade at 3-7 days. Among patients that underwent early LT, 75% survived for at least 1 year. Among patients with ≥4 organ failures, or CLIF-C ACLFs >64 at days 3-7 days, and did not undergo LT, mortality was 100% by 28 days. CONCLUSIONS: Assessment of ACLF patients at 3-7 days of the syndrome provides a tool to define the emergency of LT and a rational basis for intensive care discontinuation owing to futility.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Insuficiencia Hepática Crónica Agudizada Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Adult / Aged / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Hepatology Año: 2015 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Insuficiencia Hepática Crónica Agudizada Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Adult / Aged / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Hepatology Año: 2015 Tipo del documento: Article País de afiliación: Bélgica